Ryan Hollenbeck, MD
Interventional Cardiology · Cedar Rapids, IANPI 1689878175
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $13,594 of the $19,145 with a category attached, or 71.0%. Medtronic accounts for 84.2% of it on its own, with 30 other manufacturers making up the rest. 2025 is the largest year on record at $12,804, more than ten times the $920 reported in 2019.
Across 238 payments — averaging $80.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$16K
- Edwards Lifesciences$418
- Abbott$412
- Novartis$381
- E.r. Squibb & Sons, L.L.C.$345
- Johnson & Johnson$210
- plus $1K from 25 others
What the payments were for
- Grants$890%
- Travel & lodging$13,59471%
- Food & beverage$5,44828%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 89 | $16,113 |
| Edwards Lifesciences | 6 | $418 |
| Abbott | 17 | $412 |
| Novartis | 24 | $381 |
| E.r. Squibb & Sons, L.L.C. | 23 | $345 |
| Johnson & Johnson | 13 | $210 |
| Boston Scientific | 8 | $174 |
| Pfizer | 8 | $163 |
| Amgen | 6 | $96 |
| Sanofi-aventis U.S. LLC | 3 | $84 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $73 |
| AstraZeneca | 5 | $72 |
| Boehringer Ingelheim | 5 | $71 |
| Abiomed | 3 | $64 |
| Terumo Medical Corporation | 1 | $59 |
| Amarin Pharma, Inc. | 3 | $54 |
| Lantheus Medical Imaging, Inc. | 1 | $50 |
| Cardiovascular Systems Inc. | 2 | $37 |
| Actelion Pharmaceuticals US, Inc. | 2 | $33 |
| Teleflex LLC | 2 | $33 |
| Regeneron Healthcare Solutions, Inc. | 2 | $32 |
| Bayer | 1 | $26 |
| Bridgebio Pharma, Inc. | 1 | $21 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $19 |
| Merck | 1 | $19 |
| Siemens Medical Solutions USA, Inc. | 1 | $17 |
| Novo Nordisk | 1 | $15 |
| Bard Peripheral Vascular, Inc. | 1 | $14 |
| Philips North America LLC | 1 | $14 |
| Shockwave Medical, Inc | 1 | $13 |
| Esperion Therapeutics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$19,145 in reported general payments places this provider in the 80th percentile of 64 interventional cardiology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 506 | $493,405 |
| XareltoRivaroxaban | 237 | $238,640 |
| EntrestoSacubitril/Valsartan | 102 | $100,841 |
| Repatha SureclickEvolocumab | 109 | $85,438 |
| FarxigaDapagliflozin Propanediol | 48 | $45,472 |
| JardianceEmpagliflozin | 32 | $32,683 |
| BrilintaTicagrelor | 36 | $19,946 |
| Praluent PenAlirocumab | 15 | $14,502 |
| Metoprolol Succinate | 969 | $12,044 |
| Atorvastatin Calcium | 928 | $7,018 |
| Bumetanide | 91 | $4,686 |
| ClopidogrelClopidogrel Bisulfate | 425 | $3,152 |
| Enoxaparin Sodium | 26 | $2,875 |
| Warfarin Sodium | 375 | $2,504 |
| Rosuvastatin Calcium | 244 | $2,414 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $163 | $493,405506 claims |
| Johnson & JohnsonXarelto | $210 | $238,640237 claims |
| NovartisEntresto | $381 | $100,841102 claims |
| AstraZenecaFarxiga, Brilinta | $72 | $65,41884 claims |
| Boehringer IngelheimJardiance | $71 | $32,68332 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 64 interventional cardiology providers in Iowa.
Other interventional cardiology in Cedar Rapids
- Antony AnandarajCedar Rapids$5K
- Subhi Abu HalawaCedar Rapids$2K
- Richard KettelkampCedar Rapids$2K
- Hisham WagdyCedar Rapids$439
- Nicolas ShammasDavenport$808K
- Eric DippelDavenport$100K
- Atul ChawlaDes Moines$78K
- Magdi GhaliWest Des Moines$64K
- David McAllisterDes Moines$55K
- Daniel ShivapourDes Moines$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.